[Effect of platelet activating factor (PAF) on granulocyte migration in vivo in patients with atopic asthma].
The study was carried out in 40 patients with atopic asthma, age 16-31 years (mean 26 years) and 30 healthy volunteers, age 19-25 years (mean 20 years). In vivo granulocyte migration tests were carried out simultaneously using two methods: Southam's and the authors' original (Matusiewicz, Brzezińska). The above mentioned tests were carried out twice: the first time in December/January, the second time February/March after subcutaneous administration of PAF. The authors have demonstrated that in patients with atopic asthma a defect in migration of tissue granulocytes is present. They have also shown that PAF does not effect significantly granulocyte migration in atopic patients.
Matusiewicz
R
R
Oddział Chorób Wewnetrznych Szpitala Grochowskiego, Warszawie.
Urbankowska
B
B
Kowalczyk
M
M
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000276:immunology*; D002634:Chemotaxis, Leukocyte / Q000276:immunology*; D005260:Female; D005542:Forearm; D006801:Humans; D007279:Injections, Subcutaneous; D007958:Leukocyte Count; D008297:Male; D009504:Neutrophils / Q000276:immunology; D010972:Platelet Activating Factor / Q000008:administration & dosage / Q000502:physiology*; D012884:Skin Window Technique
D010972:Platelet Activating Factor
Wpływ czynnika aktywujacego płytki (PAF) na migracje granulocytów in vivo u chorych na astme atopowa.